All announcements

Medical Information
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

Announcement Date

Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study

July 27, 2020

Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-Based Vaccine Candidates Against SARS-COV-2

July 13, 2020

U.S. FDA Approves BAVENCIO® (avelumab) as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy


On June 30, 2020, Pfizer announced with our partner Merck KGaA that the U.S. Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. The approval is based on results from the Phase III JAVELIN Bladder 100 study, which were presented at the ASCO20 Virtual Scientific Meeting in May.
July 2, 2020

Pfizer and BioNTech announced early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-COV-2.

July 1, 2020

Approval from German authority to start clinical trial of COVID-19 vaccine

April 23, 2020

COVID-19 Information Update for U.S. Health Care Professionals

April 15, 2020

U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy.


On April 8th, 2020, Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy. The approval is based on results from the BEACON CRC trial, the only Phase 3 trial to specifically study patients with previously treated metastatic CRC with a BRAFV600E mutation.
April 8, 2020

Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development

April 1, 2020

Pfizer Outlines Five-Point Plan to Battle COVID-19


On Friday, March 13, 2020, Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
April 1, 2020

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

April 1, 2020

Pfizer Advances Battle Against COVID-19 on Multiple Fronts

April 1, 2020

COVID-19 MRNA VACCINE DEVELOPMENT PROGRAM: FIRST PARTICIPANTS IN THE U.S.


First participants dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine. Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021
April 1, 2020

Tikosyn Drug Shortage Communication – Supply Status

December 4, 2019

Partner4Better (P4B) Launches!


Pfizer Medical Information is pleased to announce the launch of the Partner4Better (P4B) global microsite where healthcare professionals (HCPs) have access to 5 educational modules- Medical Information, Counterfeits, Health Literacy, Medication Adherence and Literature Searching. Click here to access: https://www.partner4better.com/.
October 10, 2019